Oz-UK

Executive Summary

Oz-UK specializes in accelerating the commercialization of Metered Dose Inhaler (MDI) products through its proprietary MDISprint methodology. By running Chemistry, Manufacturing, and Controls (CMC) modules concurrently, the company reduces interdependencies and shortens time-to-market. Oz-UK's lean approach includes strategic partnerships with component suppliers, CDMOs for commercial-scale manufacturing, and CROs for clinical trials, enabling efficient end-to-end product development. Founded in 2015 and based in London, the company operates in the diagnostics and infectious disease sectors, though its MDI platform could extend to respiratory therapeutics. Despite limited public data on funding or valuation, Oz-UK's focus on streamlining a traditionally lengthy process positions it as a potential enabler for faster patient access to inhalable therapies.

Upcoming Catalysts (preview)

• Q3 2026Completion of first commercial-scale CMC validation batch70% success
• Q4 2026Announcement of a strategic partnership for a lead MDI product60% success
• H1 2027Initiation of a Phase 1 clinical trial for a novel inhalable therapy40% success